Project Grant K08HL183856
Award Date 8/1/26
Completion Date 4/30/31
Dollars Obligated $169K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Albert Einstein College of Medicine $693,151 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the germline genetic mechanisms underlying clonal hematopoiesis of indeterminate potential (CHIP). The research will examine how noncoding germline genetic variants confer increased risk of CHIP development by influencing the expansion of mutant hematopoietic stem and progenitor cell clones. Work...
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...
- The National Heart, Lung, and Blood Institute awarded Dana-Farber Cancer Institute, Inc., $445,000 on March 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate clonal dynamics in hematopoiesis—specifically, how hematopoietic stem cell clones expand and contract over time in healthy individuals and disease states. The award funds development of scalable methods to reconstruct clonal history without relying on invasive, slow, and costly whole-genome sequencing...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1.137883 million on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the dynamics and plasticity of the hematopoietic stem cell niche. The funded work defines niche dynamics and plasticity across development, regeneration, and hematological disease; uncovers the mechanisms regulating these processes; and develops approaches to enhance...
- The National Heart, Lung, and Blood Institute awarded New York Blood Center, Inc. $703,389 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on sex dimorphism in the bone marrow niche and its effects on hematopoietic stem cell transplantation. The research investigates how sex differences in bone marrow composition and molecular signaling influence hematopoietic stem cell transplantation success in blood disease and immune disorder...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of California, San Diego $168,795 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on proteostasis in hematopoietic stem cell development. The project, titled "Proteostasis in Hematopoietic Stem Cell Development," addresses dysfunction in inherited bone marrow failure syndromes by investigating protein homeostasis disruption in...
- The National Heart, Lung and Blood Institute awarded The University of Texas MD Anderson Cancer Center $2,448,603 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms by which telomere damage compromises hematopoietic stem cell function and to uncover therapeutic strategies to ameliorate bone marrow failure disorders. The research dissects how progressive telomere shortening, which occurs over the human lifespan, drives...
- The National Heart Lung and Blood Institute awarded Sloan-Kettering Institute For Cancer Research $281,722 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a rationally designed oral live biotherapeutic product (LBP) that delivers a defined composition of pure bacterial strains to modulate the gastrointestinal microbiome for treating acute graft-versus-host disease (AGVHD) following allogeneic hematopoietic cell transplantation. The research addresses...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Trustees of Boston University $100,228 on December 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate enhancement of engraftment potential in human hematopoietic stem cells. The research addresses the challenge of preserving hematopoietic stem cell functionality during the ex vivo culture steps required for gene editing therapies. The project employs multi-modal profiling of...